Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | DPYD | Q12882 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31357890 | 0.79 | DYRK1A (0.45) | DYRK1AGSK3BDPYDIMPDH2IMPDH1 | |
| SCHEMBL1982604 | 0.79 | DYRK1A (0.40) | DYRK1AMCL1GSK3BCHEK1CSNK2A1 | |
| SCHEMBL18130749 | 0.79 | DYRK1A (0.40) | DYRK1AMCL1GSK3BCHEK1CSNK2A1 | |
| SCHEMBL9285107 | 0.77 | GABRA1 (0.39) | DYRK1AMCL1CHEK1 | |
| SCHEMBL20514353 | 0.73 | GPR84 (0.38) | — | |
| SCHEMBL19629565 | 0.73 | NMT1 (0.34) | — | |
| SCHEMBL6039638 | 0.71 | DYRK1A (0.66) | DYRK1AMCL1GSK3BIMPDH2IMPDH1 | |
| SCHEMBL19629508 | 0.69 | EPRS1 (0.30) | — | |
| SCHEMBL18130738 | 0.69 | JAK2 (0.43) | DYRK1ACHEK1CSNK2A1MAOAMAOB | |
| SCHEMBL3065929 | 0.69 | DYRK1A (0.47) | DYRK1AMCL1GSK3BCHEK1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981962-B2 | Pyrazole derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K21 | DYRK1A 1349/4885MCL1 505/4885GSK3B 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.